Cigna price target raised to $381 from $371 at Bernstein
Bernstein raised the firm's price target on Cigna to $381 from $371 and keeps an Outperform rating on the shares ahead of quarterly results. The firm sees more potential for Cigna HC outperformance, and will be watching for continued evidence of traditional PBM margins stabilizing at expected levels. As opposed to new strategic direction, Bernstein believes the most important outcome will be increasing investor confidence in Evernorth PBM margin stability at this new lower level. Furthermore, the firm does not expect any change in guidance for 2026 given the upcoming Investor Day and its projections, which are only modestly above guidance.
Bernstein raised the firm's price target on Cigna to $381 from $371 and keeps an Outperform rating on the shares ahead of quarterly results.
The firm sees more potential for Cigna HC outperformance, and will be watching for continued evidence of traditional PBM margins stabilizing at expected levels.
As opposed to new strategic direction, Bernstein believes the most important outcome will be increasing investor confidence in Evernorth PBM margin stability at this new lower level.
Furthermore, the firm does not expect any change in guidance for 2026 given the upcoming Investor Day and its projections, which are only modestly above guidance.